ArticleThe Journal of neuropsychiatry and clinical neurosciences2021
The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions.
Article in The Journal of neuropsychiatry and clinical neurosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An update on mobile applications collecting data among subjects with or at risk of Alzheimer's disease.Frontiers in aging neuroscience · 2023Pooled it
- Utilisation of mobile apps in neurological rehabilitation practice among occupational therapists in India: a cross-sectional survey.BMC health services research · 2026Article
- Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Assessing Community Readiness to Use Social Platforms for Stroke Survivors' Recovery and Caregiver Support in Saudi Arabia.Nursing reports (Pavia, Italy) · 2025Article
- Problems and Barriers Related to the Use of Digital Health Applications: Scoping Review.Journal of medical Internet research · 2023Article
- Developments in scalable strategies for detecting early markers of cognitive decline.Translational psychiatry · 2022Review
- Assessment of Smartphone Apps for Common Neurologic Conditions (Headache, Insomnia, and Pain): Cross-sectional Study.JMIR mHealth and uHealth · 2022Article
- A systematic evaluation of primary headache management apps leveraging behavior change techniques.Cephalalgia : an international journal of headache · 2022Article
- mHealth Solutions for Mental Health Screening and Diagnosis: A Review of App User Perspectives Using Sentiment and Thematic Analysis.Frontiers in psychiatry · 2022Article
- Wearables for Neurologic Conditions: Considerations for Our Patients and Research Limitations.Neurology. Clinical practice · 2021Review
- Article
- Physiotherapists' and occupational therapists' perspectives on information and communication technology in stroke rehabilitation.PloS one · 2020Article
- Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment.Digital biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThere are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.
methodsThis was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.
resultsEighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.
conclusionsMost apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.